Windward Bio
Transforming treatment for people living with serious immunological conditions
Basel, United States · Founded 2025 · $365.0M raised
- Headquarters
- Basel
- Employees
- 1–10
- Founded
- 2025
- Business Model
- B2B
- Website
- windwardbio.com
- Total Funding
- $365.0M
- Last Round
- $165.0M Growth EquityMay 2026
- Rounds
- 2
About
Windward Bio is a clinical-stage biotechnology company committed to transforming treatment for people living with serious immunological conditions. Its lead program is WIN378, a potential best-in-disease, ultra long-acting anti-TSLP monoclonal antibody in Phase 2/3 trials for asthma and Phase 2 for COPD. The company is headquartered in Basel, Switzerland and was founded in 2025.
Summary
Windward Bio is a Biotech company based in Basel, United States, founded in 2025. It has raised $365.0M in total across 2 rounds, most recently a $165.0M Growth Equity round in May 2026. Investors include OrbiMed, Blue Owl Capital and Novo Holdings A/S.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
May 2026
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...